Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function

Jay S Skyler, Alexander Rabinovitch

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To confirm the immunological basis of type I diabetes and to determine if immune intervention alters the course of the disease, we studied the use of cyclosporine in a 1-year randomized, double-masked, placebo-controlled trial in 23 subjects enrolled within 6 weeks of diagnosis. Subjects included 12 males and 11 females, ages 9-38 years (mean, 19.7 ± 1.8 years). Initial dosage of cyclosporine was 10 mg/kg/day, given as a single daily dose, adjusted on the basis of side effects and trough cyclosporine levels. Glycemic control and insulin dosage were similar in both cyclosporine and placebo groups. The frequency of freedom from insulin usage also was similar in both groups; however, it is not possible to draw conclusions about response rates, because of the very small sample size. Glucose tolerance, as measured by rate of intravenous glucose disposal did not differ between groups. Islet β cell function was measured by determining C-peptide response to three secretogogues: intravenous glucagon, intravenous glucose, and a mixed formula meal (Sustacal). There were no differences between groups in the C-peptide responses either to intravenous glucagon or intravenous glucose. Moreover, acute insulin response to intravenous glucose was not restored in any subject. On the other hand, in comparison to the placebo group, the cyclosporine group did show an increased meal-stimulated C-peptide response after 3, 6, 9, and 12 months. When measured by regression analysis, the slope defining the rate of decline of β cell function was significantly slower for the cyclosporine group than the placebo group (p < 0.05). Thus, as measured in response to a physiological stimulus (meal challenge), cyclosporine preserves islet β cell function when used in recent onset type I diabetes. Side effects were minimal and reversible upon cessation of immune intervention. The preservation of islet β cell function by immune intervention is consistent with the hypothesis that type I diabetes has an immune mechanism involved in its pathogenesis.

Original languageEnglish
Pages (from-to)77-88
Number of pages12
JournalJournal of Diabetes and its Complications
Volume6
Issue number2
DOIs
StatePublished - Jan 1 1992

Fingerprint

Type 1 Diabetes Mellitus
Islets of Langerhans
Cyclosporine
C-Peptide
Glucose
Placebos
Meals
Insulin
Glucagon
Sample Size
Regression Analysis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function. / Skyler, Jay S; Rabinovitch, Alexander.

In: Journal of Diabetes and its Complications, Vol. 6, No. 2, 01.01.1992, p. 77-88.

Research output: Contribution to journalArticle

@article{35c6d77ef476405e8d54c7db228a0301,
title = "Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function",
abstract = "To confirm the immunological basis of type I diabetes and to determine if immune intervention alters the course of the disease, we studied the use of cyclosporine in a 1-year randomized, double-masked, placebo-controlled trial in 23 subjects enrolled within 6 weeks of diagnosis. Subjects included 12 males and 11 females, ages 9-38 years (mean, 19.7 ± 1.8 years). Initial dosage of cyclosporine was 10 mg/kg/day, given as a single daily dose, adjusted on the basis of side effects and trough cyclosporine levels. Glycemic control and insulin dosage were similar in both cyclosporine and placebo groups. The frequency of freedom from insulin usage also was similar in both groups; however, it is not possible to draw conclusions about response rates, because of the very small sample size. Glucose tolerance, as measured by rate of intravenous glucose disposal did not differ between groups. Islet β cell function was measured by determining C-peptide response to three secretogogues: intravenous glucagon, intravenous glucose, and a mixed formula meal (Sustacal). There were no differences between groups in the C-peptide responses either to intravenous glucagon or intravenous glucose. Moreover, acute insulin response to intravenous glucose was not restored in any subject. On the other hand, in comparison to the placebo group, the cyclosporine group did show an increased meal-stimulated C-peptide response after 3, 6, 9, and 12 months. When measured by regression analysis, the slope defining the rate of decline of β cell function was significantly slower for the cyclosporine group than the placebo group (p < 0.05). Thus, as measured in response to a physiological stimulus (meal challenge), cyclosporine preserves islet β cell function when used in recent onset type I diabetes. Side effects were minimal and reversible upon cessation of immune intervention. The preservation of islet β cell function by immune intervention is consistent with the hypothesis that type I diabetes has an immune mechanism involved in its pathogenesis.",
author = "Skyler, {Jay S} and Alexander Rabinovitch",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/1056-8727(92)90016-E",
language = "English",
volume = "6",
pages = "77--88",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclosporine in recent onset type I diabetes mellitus. Effects on islet β cell function

AU - Skyler, Jay S

AU - Rabinovitch, Alexander

PY - 1992/1/1

Y1 - 1992/1/1

N2 - To confirm the immunological basis of type I diabetes and to determine if immune intervention alters the course of the disease, we studied the use of cyclosporine in a 1-year randomized, double-masked, placebo-controlled trial in 23 subjects enrolled within 6 weeks of diagnosis. Subjects included 12 males and 11 females, ages 9-38 years (mean, 19.7 ± 1.8 years). Initial dosage of cyclosporine was 10 mg/kg/day, given as a single daily dose, adjusted on the basis of side effects and trough cyclosporine levels. Glycemic control and insulin dosage were similar in both cyclosporine and placebo groups. The frequency of freedom from insulin usage also was similar in both groups; however, it is not possible to draw conclusions about response rates, because of the very small sample size. Glucose tolerance, as measured by rate of intravenous glucose disposal did not differ between groups. Islet β cell function was measured by determining C-peptide response to three secretogogues: intravenous glucagon, intravenous glucose, and a mixed formula meal (Sustacal). There were no differences between groups in the C-peptide responses either to intravenous glucagon or intravenous glucose. Moreover, acute insulin response to intravenous glucose was not restored in any subject. On the other hand, in comparison to the placebo group, the cyclosporine group did show an increased meal-stimulated C-peptide response after 3, 6, 9, and 12 months. When measured by regression analysis, the slope defining the rate of decline of β cell function was significantly slower for the cyclosporine group than the placebo group (p < 0.05). Thus, as measured in response to a physiological stimulus (meal challenge), cyclosporine preserves islet β cell function when used in recent onset type I diabetes. Side effects were minimal and reversible upon cessation of immune intervention. The preservation of islet β cell function by immune intervention is consistent with the hypothesis that type I diabetes has an immune mechanism involved in its pathogenesis.

AB - To confirm the immunological basis of type I diabetes and to determine if immune intervention alters the course of the disease, we studied the use of cyclosporine in a 1-year randomized, double-masked, placebo-controlled trial in 23 subjects enrolled within 6 weeks of diagnosis. Subjects included 12 males and 11 females, ages 9-38 years (mean, 19.7 ± 1.8 years). Initial dosage of cyclosporine was 10 mg/kg/day, given as a single daily dose, adjusted on the basis of side effects and trough cyclosporine levels. Glycemic control and insulin dosage were similar in both cyclosporine and placebo groups. The frequency of freedom from insulin usage also was similar in both groups; however, it is not possible to draw conclusions about response rates, because of the very small sample size. Glucose tolerance, as measured by rate of intravenous glucose disposal did not differ between groups. Islet β cell function was measured by determining C-peptide response to three secretogogues: intravenous glucagon, intravenous glucose, and a mixed formula meal (Sustacal). There were no differences between groups in the C-peptide responses either to intravenous glucagon or intravenous glucose. Moreover, acute insulin response to intravenous glucose was not restored in any subject. On the other hand, in comparison to the placebo group, the cyclosporine group did show an increased meal-stimulated C-peptide response after 3, 6, 9, and 12 months. When measured by regression analysis, the slope defining the rate of decline of β cell function was significantly slower for the cyclosporine group than the placebo group (p < 0.05). Thus, as measured in response to a physiological stimulus (meal challenge), cyclosporine preserves islet β cell function when used in recent onset type I diabetes. Side effects were minimal and reversible upon cessation of immune intervention. The preservation of islet β cell function by immune intervention is consistent with the hypothesis that type I diabetes has an immune mechanism involved in its pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0026969225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026969225&partnerID=8YFLogxK

U2 - 10.1016/1056-8727(92)90016-E

DO - 10.1016/1056-8727(92)90016-E

M3 - Article

VL - 6

SP - 77

EP - 88

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2

ER -